Kyverna Therapeutics, Inc. KYTX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -249.21% | -388.67% | -- | -111.54% | -115.34% |
| Gross Profit | 249.21% | 388.67% | -- | 111.54% | 115.34% |
| SG&A Expenses | 22.12% | 12.65% | 24.37% | 33.91% | 90.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.40% | 1.95% | 20.02% | 40.83% | 72.75% |
| Operating Income | 7.40% | -1.95% | -20.02% | -40.83% | -72.75% |
| Income Before Tax | 3.82% | -7.55% | -26.54% | -45.49% | -73.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.82% | -7.55% | -26.54% | -45.49% | -73.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.82% | -7.55% | -26.54% | -45.49% | -73.20% |
| EBIT | 7.40% | -1.95% | -20.02% | -40.83% | -72.75% |
| EBITDA | 7.18% | -1.99% | -20.22% | -41.88% | -73.29% |
| EPS Basic | 20.07% | 2.59% | -5.71% | 86.96% | 92.80% |
| Normalized Basic EPS | 20.07% | 2.58% | -7.15% | 86.94% | 92.79% |
| EPS Diluted | 20.07% | 2.59% | -5.71% | 86.96% | 92.80% |
| Normalized Diluted EPS | 20.07% | 2.58% | -7.15% | 86.94% | 92.79% |
| Average Basic Shares Outstanding | 22.61% | 12.45% | 15.49% | 56.17% | 152.89% |
| Average Diluted Shares Outstanding | 22.61% | 12.45% | 15.49% | 56.17% | 152.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |